Vaxcyte, Inc.: updates and filings

PCVXNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$59.40

November 17, 2026Market cap $9.4B

What Ploutos Investor adds for Vaxcyte

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from 2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 24, 2026 latest annualNov 4, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 4, 2026Results of operations
    Form8-K
  • Oct 9, 2026Material agreement entered, new material financial obligation, other material events
    Form8-K
  • Oct 6, 2026Filing
    Form305B2
  • Oct 5, 2026Regulation FD disclosure, other material events
    Form8-K
  • Sep 3, 2026Officer or director change, Regulation FD disclosure
    Form8-K
  • Aug 11, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 7, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Results of operations
    Form8-K
  • Jul 15, 2026Officer or director change
    Form8-K
  • Jun 23, 2026Officer or director change
    Form8-K
  • Jun 16, 2026Shareholder vote
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 6, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 6, 2026Results of operations
    Form8-K
  • May 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 30, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 23, 2026Additional annual meeting material
    FormDEFA14A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 24, 2015.

The full analysis

What do Vaxcyte's filings show?

The filings are where every one of Vaxcyte's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.